CICR Steering Committee
Mary M. Mader, PhD
(2022-2024)Vice-President
Molecular Innovation
Indiana Biosciences Research Institute
Indianapolis, Indiana
Joachim Rudolph, PhD
(2022-2023)Principal Scientist
Discovery Chemistry
Genentech, Inc.
South San Francisco, California
Rima Al-awar, PhD
(2021-2024)Head, Therapeutic Innovation and Drug Discovery
Ontario Institute for Cancer Research
Toronto, Canada
Michelle Arkin, PhD
(2021-2024)Professor, Pharmaceutical Chemistry, School of Pharmacy
University of California San Francisco
San Francisco, California
Sara Buhrlage, PhD
(2022-2025)Associate Professor
Cancer Biology, Dana-Farber Cancer Institute
Biological Chemistry and Molecular Pharmacology
Harvard Medical School
Boston, Massachusetts
Danette L. Daniels, PhD
(2022-2025)Vice-President
Protein Degrader Platform
Foghorn Therapeutics
Cambridge, Massachusetts
Laura D’Agostino, PhD
(2020-2023)Director
Bristol Myers Squibb
Cambridge, Massachusetts
Benjamin L. Ebert, PhD
(2021-2024)George P. Canellos, MD, and Jean S. Canellos Professor of Medicine
Harvard Medical School;
Chair of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts
Adrian L. Gill, PhD
(2020-2023)Vice President, Medicinal Chemistry
Revolution Medicines
Redwood City, California
Ingo Hartung, PhD
(2021-2024)Director and Head of Medicinal Chemistry GER
Merck Healthcare KGaA
Darmstadt, Germany
David Millan, PhD
(2021-2024)Vice President, Head of Chemistry
Foghorn Therapeutics
Cambridge, Massachusetts
Christopher Nasveschuk, PhD
(2020-2023)Vice President, Chemistry
C4 Therapeutics
Watertown, Massachusetts
Daniel K. Nomura, PhD
(2022-2025)Professor of Chemical Biology
Department of Chemistry
University of California, Berkeley
Jennifer C. Petter, PhD
(2022-2025)Founder and Chief Innovation Officer
Arrakis Therapeutics
Waltham, Massachusetts
Zoran Rankovic, PhD
(2020-2023)Director, CBT Chemistry Centers
St. Jude Children’s Research Hospital
Memphis, Tennessee
Hong Shen, PhD
(2022-2025)Head of China Innovation Center of Roche
Shanghai, China